Jumana ALBARAMKİ, Haitham DMOUR, Mohammad SHBOUL, Carine BONNARD, Byrappa VENKATESH, Rasha ODEH

Recessive mutation in GALNT3 causes hyperphosphatemic familial tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis

Hyperphosphatemic familial tumoral calcinosis is a rare autosomal recessivedisorder that is characterized by persistent hyperphosphatemia andextra-articular calcifications. Three cases were previously reported withhyperphosphatemic familial tumoral calcinosis that were associated withchronic recurrent multifocal osteomyelitis, an autoinflammatory disorderthat is characterized by recurrent episodes of bone pain. We describe herean 11-year-old child who was diagnosed with these two conditions and wasfound to carry a splice site mutation c.1524+1G>A in the GALNT3 gene.

PDF

___

1. Farrow EG, Imel EA, White KE. Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and αKlotho). Best Pract Res Clin Rheumatol 2011; 25: 735-747.

2. Majeed SA. Chronic recurrent multifocal osteomyelitis associated with tumoral calcinosis. J Bone Joint Surg Br 1994; 76: 325-327.

3. Maus U, Ihme N, Schroeder S, et al. Chronic recurrent multifocal osteomyelitis and tumoral calcinosis--is there an association? Klin Padiatr 2007; 219: 277-281.

4. Demellawy DE, Chang N, de Nanassy J, Nasr A. GALNT3 gene mutation-associated chronic recurrent multifocal osteomyelitis and familial hyperphosphatemic familial tumoral calcinosis. Scand J Rheumatol 2015; 44: 170-172.

5. Ferguson PJ, El-Shanti HI. Autoinflammatory bone disorders. Curr Opin Rheumatol 2007; 19: 492-498.

6. Yüksel HY, Yılmaz S, Gürbüzel M. Normophosphatemic type tumoral calcinosis associated with chronic recurrent multifocal osteomyelitis: A case report. Acta Orthop Traumatol Turc 2011;45 :124-129.

7. Rafaelsen S, Johansson S, Ræder H, Bjerknes R. Longterm clinical outcome and phenotypic variability in hyperphosphatemic familial tumoral calcinosis and hyperphosphatemic hyperostosis syndrome caused by a novel GALNT3 mutation; case report and review of the literature. BMC Genet 2014; 24:15-98.

8. Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A 2010; 152A: 896-903.

9. Frishberg Y, Topaz O, Bergman R, et al. Identification of a recurrent mutation in GALNT3 demonstrates that hyperostosis-hyperphosphatemia syndrome and familial tumoral calcinosis are allelic disorders. J Mol Med (Berl) 2005; 83: 33-38.

10. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579-581.

11. Lammoglia JJ, Mericq V. Familial tumoral calcinosis caused by a novel FGF23 mutation: Response to induction of tubular renal acidosis with acetazolamide and the non-calcium phosphate binder sevelamer. Horm Res 2009; 71: 178-184.

12. Balachandran K, Kamalanathan S, Sahoo JP, Das AK, Halanaik D. Differential response of idiopathic sporadic tumoral calcinosis to bisphosphonates. Indian J Endocrinol Metab 2014; 18: 521-525.

13. Finer G, Price HE, Shore RM, White KE, Langman CB. Hyperphosphatemic familial tumoral calcinosis: response to acetazolamide and postulated mechanisms. Am J Med Genet A 2014; 164A: 1545-1549.